UPC APP 4496/2025

—·EP4183412: RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Sonstige prozessuale
Parteien: Kläger
GlaxoSmithKline Biologicals SA
Vertreter: Oliver Jan Jüngst (Bird & Bird LLP); Luca Brons (Bird & Bird LLP)
Beklagte
Pfizer Europe MA EEIG
Pfizer Manufacturing Belgium NV
Pfizer Pharma GmbH
Pfizer Corporation Austria GmbH
Pfizer S.A.
Pfizer Aps
Pfizer Oy
Pfizer SAS
Pfizer S.r.l.
Pfizer B.V.
Laboratórios Pfizer, Lda.
Pfizer AB
Pfizer Luxembourg S.a.r.l.
Pfizer Service Company S.R.L.
Vertreter: Gareth Williams (Marks & Clerk LLP); Claudia Milbradt (Clifford Chance); Tobias J. Hessel (Clifford Chance)
Division: Dusseldorf LD
Richter: Ronny Thomas · Presiding judge
Jule Schumacher · Legally qualified judge and judge-rapporteur
Andrea Postiglione · Legally qualified judge
Technology: Biotechnology
Sprache: —
Erste Entscheidung: 4. März 2025

Entscheidungen

2025-03-04
Generic application
The Düsseldorf Local Division issued a procedural order in the GlaxoSmithKline v Pfizer RSV vaccine case (EP4183412), deciding to bifurcate by referring the counterclaim for revocation to the Milan Central Division while proceeding with the infringement action, and granting a one-month extension for Pfizer's rejoinder.
Rechtsfragen:Bifurcation (Art. 33(3) UPCA)Referral of counterclaim for revocation to Central DivisionExtension of time period (R.9.3(a) RoP)Procedural efficiency

Dokumente